Order Article Reprints

Kucukevcilioglu M, Yeşiltaş YS, Durukan AH, Unlu N, Onen M, Alp MN, Kalayci D, Acar MA, Sekeroglu MA, Citirik M, et al. Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch. Medicina. 2023; 59(2):263. https://doi.org/10.3390/medicina59020263

Kucukevcilioglu, Murat, Yağmur Seda Yeşiltaş, Ali Hakan Durukan, Nurten Unlu, Mehmet Onen, Mehmet Numan Alp, Defne Kalayci, Mehmet Akif Acar, Mehmet Ali Sekeroglu, Mehmet Citirik, and et al. 2023. "Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch" Medicina 59, no. 2: 263. https://doi.org/10.3390/medicina59020263

Kucukevcilioglu, M., Yeşiltaş, Y. S., Durukan, A. H., Unlu, N., Onen, M., Alp, M. N., Kalayci, D., Acar, M. A., Sekeroglu, M. A., Citirik, M., Altintas, A. G. K., Hazirolan, D., Ozdal, P. C., Toklu, Y., Bicer, T., Ugurlu, N., Budakoglu, O., Yazar, Z., Zeki, N. I. U., ... Baskan, C. (2023). Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch. Medicina, 59(2), 263. https://doi.org/10.3390/medicina59020263